BR112018006820A2 - anticorpos anti-psa (5a10) humanizados - Google Patents
anticorpos anti-psa (5a10) humanizadosInfo
- Publication number
- BR112018006820A2 BR112018006820A2 BR112018006820A BR112018006820A BR112018006820A2 BR 112018006820 A2 BR112018006820 A2 BR 112018006820A2 BR 112018006820 A BR112018006820 A BR 112018006820A BR 112018006820 A BR112018006820 A BR 112018006820A BR 112018006820 A2 BR112018006820 A2 BR 112018006820A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- chain variable
- variable region
- amino acid
- acid sequences
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 abstract 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
trata-se de polipeptídeos de anticorpo com especificidade de ligação para antígeno específico de próstata (psa), em que o polipeptídeo de anticorpo compreende (a) uma região variável de cadeia pesada que compreende as sequências de aminoácido de seq id no:1 e seq id no:2 e seq id no:3 e/ou (b) uma região variável de cadeia leve que compreende as sequências de aminoácido de seq id no:4 e seq id no:5 e seq id no:6, e em que a região variável de cadeia pesada e a região variável de cadeia leve compreendem sequências de aminoácido de estrutura de um ou mais anticorpos humanos. a invenção adicionalmente fornece uso dos ditos polipeptídeos de anticorpo no diagnóstico e tratamento de câncer de próstata.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1517550.8A GB201517550D0 (en) | 2015-10-05 | 2015-10-05 | Antibody polypeptides and uses thereof |
GBGB1519105.9A GB201519105D0 (en) | 2015-10-29 | 2015-10-29 | Antibody polypeptides and uses thereof |
PCT/EP2016/073684 WO2017060247A1 (en) | 2015-10-05 | 2016-10-04 | Humanized anti psa (5a10) antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018006820A2 true BR112018006820A2 (pt) | 2018-10-23 |
Family
ID=57113327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018006820A BR112018006820A2 (pt) | 2015-10-05 | 2016-10-04 | anticorpos anti-psa (5a10) humanizados |
Country Status (19)
Country | Link |
---|---|
US (2) | US11332543B2 (pt) |
EP (2) | EP3359189B1 (pt) |
JP (1) | JP6916797B2 (pt) |
KR (1) | KR20180053756A (pt) |
CN (1) | CN108136013B (pt) |
AU (1) | AU2016334715B2 (pt) |
BR (1) | BR112018006820A2 (pt) |
CA (1) | CA2998818A1 (pt) |
DK (1) | DK3359189T3 (pt) |
ES (1) | ES2880682T3 (pt) |
HK (1) | HK1258674A1 (pt) |
IL (1) | IL258189B2 (pt) |
LT (1) | LT3359189T (pt) |
MX (1) | MX2018004071A (pt) |
PL (1) | PL3359189T3 (pt) |
PT (1) | PT3359189T (pt) |
RU (1) | RU2753677C2 (pt) |
WO (1) | WO2017060247A1 (pt) |
ZA (1) | ZA201802019B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
AU2021212659A1 (en) | 2020-01-28 | 2022-08-04 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
FI20002127A0 (fi) * | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
CN101098891B (zh) | 2005-01-05 | 2014-05-21 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
JP6067222B2 (ja) * | 2008-07-15 | 2017-01-25 | ジェネンテック, インコーポレイテッド | アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途 |
JP2010004895A (ja) * | 2009-10-13 | 2010-01-14 | Hiroshima Univ | ヒト化ニワトリ抗体の製造方法 |
BR112014010739A2 (pt) * | 2011-10-28 | 2017-04-25 | Fredax Ab | agentes terapêuticos e uso dos mesmos |
RU2537263C2 (ru) | 2012-10-22 | 2014-12-27 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" | Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты) |
GB2520353A (en) * | 2013-11-19 | 2015-05-20 | Fredax Ab | Antibody polypeptides and uses thereof |
MX2016012667A (es) * | 2014-03-28 | 2017-01-09 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico de cancer de prostata. |
-
2016
- 2016-10-04 JP JP2018536343A patent/JP6916797B2/ja active Active
- 2016-10-04 PT PT167783307T patent/PT3359189T/pt unknown
- 2016-10-04 PL PL16778330T patent/PL3359189T3/pl unknown
- 2016-10-04 BR BR112018006820A patent/BR112018006820A2/pt active Search and Examination
- 2016-10-04 RU RU2018115734A patent/RU2753677C2/ru active
- 2016-10-04 DK DK16778330.7T patent/DK3359189T3/da active
- 2016-10-04 WO PCT/EP2016/073684 patent/WO2017060247A1/en active Application Filing
- 2016-10-04 MX MX2018004071A patent/MX2018004071A/es unknown
- 2016-10-04 IL IL258189A patent/IL258189B2/en unknown
- 2016-10-04 EP EP16778330.7A patent/EP3359189B1/en active Active
- 2016-10-04 CN CN201680059166.8A patent/CN108136013B/zh active Active
- 2016-10-04 AU AU2016334715A patent/AU2016334715B2/en active Active
- 2016-10-04 EP EP21173910.7A patent/EP3922265A1/en not_active Withdrawn
- 2016-10-04 LT LTEPPCT/EP2016/073684T patent/LT3359189T/lt unknown
- 2016-10-04 US US15/761,260 patent/US11332543B2/en active Active
- 2016-10-04 CA CA2998818A patent/CA2998818A1/en active Pending
- 2016-10-04 KR KR1020187012299A patent/KR20180053756A/ko not_active Application Discontinuation
- 2016-10-04 ES ES16778330T patent/ES2880682T3/es active Active
-
2018
- 2018-03-27 ZA ZA2018/02019A patent/ZA201802019B/en unknown
-
2019
- 2019-01-21 HK HK19101041.6A patent/HK1258674A1/zh unknown
-
2022
- 2022-04-11 US US17/717,254 patent/US20220242969A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL258189B (en) | 2022-11-01 |
RU2018115734A3 (pt) | 2020-03-27 |
LT3359189T (lt) | 2021-07-26 |
EP3922265A1 (en) | 2021-12-15 |
EP3359189A1 (en) | 2018-08-15 |
CN108136013A (zh) | 2018-06-08 |
WO2017060247A1 (en) | 2017-04-13 |
US11332543B2 (en) | 2022-05-17 |
CA2998818A1 (en) | 2017-04-13 |
RU2018115734A (ru) | 2019-11-07 |
ES2880682T3 (es) | 2021-11-25 |
US20220242969A1 (en) | 2022-08-04 |
ZA201802019B (en) | 2021-09-29 |
IL258189B2 (en) | 2023-03-01 |
US20180273634A1 (en) | 2018-09-27 |
EP3359189B1 (en) | 2021-06-23 |
AU2016334715B2 (en) | 2023-02-02 |
MX2018004071A (es) | 2018-11-09 |
KR20180053756A (ko) | 2018-05-23 |
DK3359189T3 (da) | 2021-07-05 |
IL258189A (en) | 2018-05-31 |
AU2016334715A1 (en) | 2018-04-12 |
HK1258674A1 (zh) | 2019-11-15 |
PL3359189T3 (pl) | 2021-12-20 |
JP2018531045A (ja) | 2018-10-25 |
JP6916797B2 (ja) | 2021-08-11 |
CN108136013B (zh) | 2023-04-18 |
RU2753677C2 (ru) | 2021-08-19 |
PT3359189T (pt) | 2021-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
WO2018031490A3 (en) | Anti-ox40 binding proteins | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
WO2018069871A3 (en) | Anti-kras binding proteins | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
BR112018006820A2 (pt) | anticorpos anti-psa (5a10) humanizados | |
MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
BR112018068637A2 (pt) | podocalixina e anticorpo relacionado a tra, métodos de preparação e usos como agente terapêutico anticancerígeno | |
MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |